In timely fashion, US pharma giant Pfizer (NYSE: PFE) has received US Food and Drug Administration (FDA) approval for Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Besponsa has made it to approval quickly, having only been granted priority review status by the FDA in February. It has also won the nod ahead of Swiss pharma giant Novartis’ (NOVN: VX) CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy which looks set to get FDA approval in this indication later this year, albeit for the pediatric and adult patient group.
Although Kite Pharma (Nasdaq: KITE) is also in the race, tisagenlecleucel-T, which Novartis is also evaluating for other indications, is likely to be the first of the new drug type to reach market, though it has still not beaten Besponsa to the final clearance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze